Smith Karen L.    SEC # 1639637

        

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

Relationships

        

18  Owner Relationships  (where the Issuers of the  Smith Karen L.-owned  securities are...)

First		Latest Filing		Filing		Issuer / Subject
		8/21/23		3			Aurinia Pharmaceuticals Inc.
		8/21/23		4			"
5/17/22		6/14/23		4		NY	Tourmaline Bio, Inc. [ formerly Talaris Therapeutics, Inc. ]
6/28/18		6/5/23		4		CA	Sangamo Therapeutics, Inc.
5/23/22		2/2/23		4		CA	Quince Therapeutics, Inc. [ formerly Cortexyme, Inc. ]
3/5/19		5/26/22		4		NJ	Antares Pharma, Inc.
		5/23/22		3		CA	Quince Therapeutics, Inc. [ formerly Cortexyme, Inc. ]
		5/17/22		3		NY	Tourmaline Bio, Inc. [ formerly Talaris Therapeutics, Inc. ]
11/15/17		11/22/21		4		MA	Acceleron Pharma Inc.
2/26/21		5/11/21		4		MD	Emergent BioSolutions Inc.
		5/28/20		3			"
		3/5/19		3		NJ	Antares Pharma, Inc.
		6/28/18		3		CA	Sangamo Therapeutics, Inc.
5/13/15		3/7/18		4			Jazz Pharmaceuticals plc
		2/13/18		4		MD	Sucampo Pharmaceuticals, Inc.
		11/15/17		3		MA	Acceleron Pharma Inc.
		7/27/17		3		MD	Sucampo Pharmaceuticals, Inc.
		4/23/15		3			Jazz Pharmaceuticals plc

        

No  Issuer Relationships  (where the Owners of the  Smith Karen L.  securities are...)

        

10  Insider & Control Relationships  (Directors & Officers, Owners, Parent / Subs., et al.)

First		Latest Filing		Relationship		Registrant
		8/21/23		Director	of		Aurinia Pharmaceuticals Inc.
5/17/22		6/14/23		Director	of	NY	Tourmaline Bio, Inc. [ formerly Talaris Therapeutics, Inc. ]
6/28/18		6/5/23		Director	of	CA	Sangamo Therapeutics, Inc.
5/23/22		2/2/23		Officer:  Chief Medical Officer	of	CA	Quince Therapeutics, Inc. [ formerly Cortexyme, Inc. ]
3/5/19		5/26/22		Director	of	NJ	Antares Pharma, Inc.
11/15/17		11/22/21		Director	of	MA	Acceleron Pharma Inc.
5/28/20		5/11/21		Officer:  EVP, Chief Medical Officer	of	MD	Emergent BioSolutions Inc.
5/12/17		3/7/18		Officer:  EVP, R&D & CMO	of		Jazz Pharmaceuticals plc
7/27/17		2/13/18		Director	of	MD	Sucampo Pharmaceuticals, Inc.
4/23/15		3/6/17		Officer:  Global Head of R&D & CMO	of		Jazz Pharmaceuticals plc

        

No  Joint-Filer Relationships  (Co-Filer Registrants:  Partners, Affiliates, et al.)

        

No  Group-Member Relationships  (Co-Filer Non-Registrants:  Partners, Affiliates, et al.)

        

Filing Agent Relationships  (SEC Filing Agents, Attorneys, Printers, et al. — Affiliates:  Directors & Officers, et al.)

9  Filing Agents and/or Registrants have submitted Filings for  Smith Karen L.:

Latest Filing				Filing Agentª, Registrant or SEC — SEC #			Filings
		Type
8/21/23		4			Aurinia Pharmaceuticals Inc. — 1600620		2
6/14/23		4		IL	DONNELLEY FINANCIAL SOLUTIONS File16/FA — 1209191		18
6/13/22		4		TX	Donnelley Financial Solutions 06/FA [ formerly Dfin Solutions 06/FA ] — 899243		4
11/22/21		4		TX	Toppan Merrill/FA — 1104659		1
5/11/21		4		MD	Emergent BioSolutions Inc. — 1367644		3
4/5/21		4		TX	Section16 Direct/FA — 1179110		8
3/7/18		4			Jazz Pharmaceuticals plc — 1232524		10
2/13/18		4		CA	Globenewswire Inc./FA — 1171843		2
5/12/17		4			No Filing Agent:  Self-filed — 1639637		4
Total:							52
__________  ª  Proprietary to SEC Info℠:  The SEC does not publish the names of SEC Filing Agents.